Extended-spectrum AmpC cephalosporinase in Acinetobacter baumannii: ADC-56 confers resistance to cefepime.

Antimicrob Agents Chemother

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Scaife Hall S829, 3550 Terrace Street, Pittsburgh, PA 15261, USA.

Published: October 2011

ADC-56, a novel extended-spectrum AmpC (ESAC) β-lactamase, was identified in an Acinetobacter baumannii clinical isolate. ADC-56 possessed an R148Q change compared with its putative progenitor, ADC-30, which enabled it to hydrolyze cefepime. Molecular modeling suggested that R148 interacted with Q267, E272, and I291 through a hydrogen bond network which constrained the H-10 helix. This permitted cefepime to undergo conformational changes in the active site, with the carboxyl interacting with R340, likely allowing for better binding and turnover.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186995PMC
http://dx.doi.org/10.1128/AAC.00704-11DOI Listing

Publication Analysis

Top Keywords

extended-spectrum ampc
8
acinetobacter baumannii
8
ampc cephalosporinase
4
cephalosporinase acinetobacter
4
baumannii adc-56
4
adc-56 confers
4
confers resistance
4
resistance cefepime
4
cefepime adc-56
4
adc-56 novel
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!